Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vertex Pharmaceuticals has announced interim data from two treatment arms of the Phase II ZENITH study of Interferon-Free (All-Oral) treatment regimen of INCIVEK, VX-222 and Ribavirin in People with Genotype 1 Hepatitis C.
Subscribe to our email newsletter
The data showed that viral loads were below the lower limit of quantification for 80% (37/46) of patients with genotype 1 hepatitis C at week two and 83% (38/46) of patients with genotype 1 at week 12.
Eleven patients met the criteria of having undetectable hepatitis C virus at weeks two and eight of treatment and were therefore eligible to stop all treatment at 12 weeks.
Nine of these 11 patients achieved SVR4 (undetectable hepatitis C virus four weeks after the end of all treatment), the company said.
The three drug regimen was generally well-tolerated.